# US 2026/0285824 A1 · Butenolide-based estrogen receptor alpha inhibitors and degraders and method of using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0285824 A1
- Document ID: US20260285824A1
- Status: Published application
- Kind: A1
- Application number: 19/565,396
- Filed: 2026-03-12
- Published: 2026-09-24
- Earliest claimed: 2025-03-12
- Assignees: Georgia Tech Research Corporation
- Applicants: Georgia Tech Research Corporation
- Inventors: Adegboyega Oyelere; Dipak Walunj; Alexis Johnston; Jeremiah Olugbami
- Web page: https://patentgrep.com/patent/US20260285824A1

## CPC

- C07D 307/58: One oxygen atom, e.g. butenolide
- A61K 31/365: Lactones
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/4192: 1,2,3-Triazoles
- A61K 31/443: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 35/00: Antineoplastic agents
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An exemplary embodiment of the present disclosure provides a compound of formula (I) having the following structure: or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, wherein R1, R2, R3, X, W1, Y1, Z1, W2, Y2, Z2 are as described herein. The present disclosure also provides compositions comprising these compounds and methods of using these compounds to inhibit or degrade an estrogen receptor alpha, particularly for the treatment of cancer.

## Claims

### Claim 1

A compound of formula (I) having the following structure:
or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, wherein
R1 is optionally present, and when present is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —CH2R6, —OR6 or —SR6;
R2 is optionally present, and when present is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —CH2R6, —OR6 or —SR6;
R3 is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —CH2R6, —OR6 or —SR6;
X is O or NR7;
W1 is C or N, wherein when W1 is N, R1 is not present;
Y1 is CH or N;
Z1 is CH or N;
W2 is C or N, wherein when W2 is N, R2 is not present;
Y2 is CH or N;
Z2 is CH or N;
R4 is H, C1-C6 alkyl, C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —N(CH3)2 or heterocyclyl;
R5 is H or C1-C6 alkyl; or
R4 and R5 combine with the nitrogen atom to which they are attached to form a heterocyclic ring, wherein the heterocyclic ring can be substituted with C1-C6 alkyl;
R6 is C1-C6 alkyl or C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —NR4R5, heteroaryl, or heterocyclyl; and
R7 is H, C1-C6 alkyl, or C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —NR4R5, heteroaryl, or heterocyclyl.

### Claim 2 (depends on 1)

The compound according to claim 1, selected from the group consisting of

### Claim 3

A compound of formula (I) having the following structure:
or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, wherein
R1 is optionally present, and when present is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —OR6 or —SR6;
R2 is optionally present, and when present is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —OR6 or —SR6;
R3 is H, hydroxyl, —SO2C1-6 alkyl, —NR4R5, —CN, heterocyclyl, aryl, heteroaryl, —OR6 or —SR6;
X is O or NR7;
W1 is C or N, wherein when W1 is N, R1 is not present;
Y1 is CH or N;
Z1 is CH or N;
W2 is C or N, wherein when W2 is N, R2 is not present;
Y2 is CH or N;
Z2 is CH or N;
R4 is H, C1-C6 alkyl, C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —N(CH3)2 or heterocyclyl;
R5 is H or C1-C6 alkyl; or
R4 and R5 combine with the nitrogen atom to which they are attached to form a heterocyclic ring, wherein the heterocyclic ring can be substituted with C1-C6 alkyl;
R6 is C1-C6 alkyl or C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —NR4R5, heteroaryl, or heterocyclyl; and
R7 is H, C1-C6 alkyl, or C2-C6 alkenyl, wherein C1-C6 alkyl and C2-C6 alkenyl can be substituted with —NR4R5, heteroaryl, or heterocyclyl.

### Claim 4 (depends on 3)

The compound according to claim 3, selected from the group consisting of

### Claim 5 (depends on 1)

A method of treating cancer in a subject, said method comprising:
providing a compound according to claim 1 to a subject in need of said treatment.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer is an estrogen receptor (ER) dependent cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, and liver cancer.

### Claim 8 (depends on 3)

A method of treating cancer in a subject, said method comprising:
providing a compound according to claim 3 to a subject in need of said treatment.

### Claim 9 (depends on 8)

The method of claim 8, wherein the cancer is an estrogen receptor (ER) dependent cancer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cancer is selected from the group consisting of breast cancer, prostate cancer, lung cancer, and liver cancer.

### Claim 11 (depends on 1)

A method of inhibiting an estrogen receptor alpha, said method comprising:
providing a compound according to claim 1 under conditions effective to inhibit the estrogen receptor alpha (ERα).

### Claim 12 (depends on 3)

A method of inhibiting an estrogen receptor alpha, said method comprising:
providing a compound according to claim 3 under conditions effective to inhibit the estrogen receptor alpha (ERα).

### Claim 13 (depends on 1)

A method of degrading an estrogen receptor alpha, said method comprising:
providing a compound according to claim 1 under conditions effective to degrade the estrogen receptor alpha (ERα).

### Claim 14 (depends on 3)

A method of degrading an estrogen receptor alpha, said method comprising:
providing a compound according to claim 3 under conditions effective to degrade the estrogen receptor alpha (ERα).

### Claim 15 (depends on 1)

A method of treating a hyperproliferative disorder, said method comprising:
providing a compound according to claim 1 under conditions effective to treat a hyperproliferative disorder.

### Claim 16 (depends on 15)

The method of claim 15, wherein the hyperproliferative disorder depends on ERα, RET, GREB1, ADCY5 or TFF1.

### Claim 17 (depends on 15)

The method of claim 15, wherein the hyperproliferative disorder is a cancer selected from the group consisting of breast cancer, prostate cancer, lung cancer, and liver cancer.

### Claim 18 (depends on 3)

A method of treating a hyperproliferative disorder, said method comprising:
providing a compound according to claim 3 under conditions effective to treat a hyperproliferative disorder.

### Claim 19 (depends on 1)

A composition comprising:
a compound according to claim 1; and
a carrier.

### Claim 20 (depends on 3)

A composition comprising:
a compound according to claim 3; and
a carrier.
